WeForNews | Latest News, Breaking News, News Updates Warship INS Godavari to be decommissioned Today | WeForNews | Latest News, Blogs
Connect with us

India

Warship INS Godavari to be decommissioned Today

Published

on

India’s first indigenously designed and built warship INS Godavari will be decommissioned on Wednesday in Mumbai, 32 years after it was inducted into the Indian Navy.

Over the past three decades, Godavari has successfully been deployed in numerous operations including Operation Jupiter – 1988 (Sri Lanka), Operation Shield and Operation Bolster – 1994 (de-induction of the Indian Army from Somalia) and Patrol of Gulf of Aden (PoG) – 2009 and 2011 (anti-piracy operations in the Gulf of Aden).

In 1988, in an operation called Operation Cactus, India successfully thwarted a coup d’état​ against the Maldivian Government, a Navy official said.

Godavari and INS Betwa intercepted and arrested the mercenaries, who tried to flee Male on board the Merchant Vessel Progress Light.

The mercenaries were later handed over to Male, earning great respect and goodwill for India in the international community.

Being the first indigenously designed and constructed ship, INS Godavari was showcased around the world as a symbol of India’s growing military might and self-reliance and the warship has also participated in numerous operations and deployments, across the expanse of the Indian Ocean and
beyond.

Godavari class frigates were armed with surface to surface and surface to air guided missiles. INS Godavari was also among of the first frigates in the world capable of carrying two Sea King helicopters.

Cities

Delhi reports 51 cases of minor adverse events post vaccination

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Published

on

By

Covid 19 Vaccine

Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.

Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC’s Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.

Follow our coverage of the coronavirus crisis here

Continue Reading

Health

Bharat Biotech to pay compensation if Covaxin causes side-effects

The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19

Published

on

By

COVAXIN Corona Covid vaccine

Hyderabad, January 16: Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said: “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.

In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However, the clinical efficacy of the vaccine was yet to be established and it was still being studied in phase 3 clinical trials, the vaccine maker said.

“Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed,” the consent form said.

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Suchitra Ella, joint managing director, Bharat Biotech International Limited, on her Twitter account said: “Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.” — PTI

Continue Reading

Cities

AIIMS security guard reports allergy post COVID vaccination, in hospital care

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

Published

on

By

Vaccine

New Delhi, January 16

A 22-year-old security guard at AIIMS, New Delhi reported allergic reaction and is learnt to be in intensive care, moments after the government said there was no post-vaccine hospitalisation.

The 22-year-old guard developed headache, rash, respiratory distress, tachycardia after vaccination. He is in ICU and his condition is stable, hospital sources said.

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

All beneficiaries vaccinated at AIIMS got indigenous COVAXIN.

Continue Reading
Advertisement

Most Popular